Contact us

Let’s talk about your next CDx project

Biopharma Partnerships

You agree to be contacted with newsletters, marketing or promotional materials and other information that may be of interest to you. You may opt-out of receiving communications from us by following the unsubscribe link or the instructions provided in any email we send. For further information on our privacy practices and commitment to protecting your privacy, please visit our Privacy Policy.

Hidden Fields

Companion diagnostic development

With Myriad, you gain an innovative, practical, and responsive CDx lab partner, focused on delivering value.

Companion diagnostic development

With Myriad, you gain an innovative, practical, and responsive CDx lab partner, focused on delivering value.

Supporting your CDx project from prototype to commercialization

From custom assay development through global regulatory clearance and commercialization, we have the deep expertise required to deliver results every step of the way.






Global regulatory expertise

Working closely with regulatory agencies worldwide, Myriad has secured approvals for 10 companion diagnostics (CDx) claims in the U.S. and Japan, as well as CE marking in Europe. In China, we support clinical trials using MyChoice® CDx testing.

CDx commercialization powerhouse

Your partner in CDx development should go far beyond an assay design. Using our centralized testing operations, pre-existing sales and marketing infrastructure, and key laboratory partnerships, Myriad helps drive your CDx test and your therapy across the finish line and into the market.

QIAGEN partnership enables global companion diagnostic kit development and commercialization

Combining our strengths in assay development, clinical testing and regulatory approvals, our partnership with QIAGEN offers pharma partners comprehensive global development of lab-developed and/or distributable kit-based companion diagnostic tests.

Logos of Myriad and QIAGEN
Logos of Myriad and illumina

Learn more about our partnership with sequencing giant Illumina

By leveraging our respective strengths in HRD and comprehensive genomic profiling, we seek to broaden clinical research opportunities to drive CDx development for gene-based therapies worldwide.

Approved diagnostic tests

Myriad has a proven track record of successful CDx test development, offering two FDA-approved CDx tests.

MyChoice® CDx

HRD Companion Diagnostic Test

Determines homologous recombination deficiency (HRD) status for patients with ovarian cancer using MyChoice CDx, the first and only FDA-approved, NGS-based IVD tumor test

  • Informs early- and late-line treatment decisions
  • Approved to guide treatment selection for PARP inhibitor therapies

BRACAnalysis CDx®

Germline Companion Diagnostic Test

Identifies patients with deleterious or suspected deleterious mutations in BRCA1 or BRCA2 genes who may be eligible for certain targeted therapies, the first and only FDA-approved CDx test of its kind

  • Approved for use with patients diagnosed with ovarian, breast, prostate or pancreatic cancer
  • Identifies patients most likely to benefit from PARP inhibitor treatment
  • VUS rates are minimized with our unparalleled variant classification expertise